AWM Investment Company Inc. Increases Stake in MDxHealth SA $MDXH

Key Points

• AWM Investment Company Inc. increased its stake in MDxHealth SA by 10.6%, owning 5,221,282 shares valued at approximately $7.41 million as of its latest SEC filing.
• Several analysts have assigned buy ratings to MDxHealth, with a consensus price target of $7.00 and recent upgrades indicating growing confidence in the company's stock.
• MDxHealth reported disappointing earnings, posting a loss of ($0.15) per share for the latest quarter, missing expectations, and guiding for similar performance in Q2 2025.

AWM Investment Company Inc. lifted its stake in MDxHealth SA (NASDAQ:MDXH - Free Report) by 10.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,221,282 shares of the company's stock after acquiring an additional 499,992 shares during the quarter. AWM Investment Company Inc. owned 11.04% of MDxHealth worth $7,414,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Northern Trust Corp bought a new stake in MDxHealth during the fourth quarter valued at approximately $1,033,000. Renaissance Technologies LLC lifted its holdings in MDxHealth by 715.2% during the fourth quarter. Renaissance Technologies LLC now owns 123,100 shares of the company's stock valued at $292,000 after purchasing an additional 108,000 shares in the last quarter. Delta Investment Management LLC lifted its holdings in MDxHealth by 459.1% during the first quarter. Delta Investment Management LLC now owns 190,100 shares of the company's stock valued at $270,000 after purchasing an additional 156,100 shares in the last quarter. Perkins Capital Management Inc. lifted its holdings in MDxHealth by 20.1% during the first quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company's stock valued at $1,678,000 after purchasing an additional 198,000 shares in the last quarter. Finally, Castleview Partners LLC purchased a new position in MDxHealth during the first quarter valued at approximately $48,000.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Wall Street Zen raised shares of MDxHealth to a "hold" rating in a report on Saturday, August 30th. Craig Hallum assumed coverage on shares of MDxHealth in a report on Thursday, July 17th. They set a "buy" rating and a $8.00 price target on the stock. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $7.00.

MDxHealth Price Performance

Shares of MDXH stock remained flat at $3.53 during mid-day trading on Friday. 62,011 shares of the stock traded hands, compared to its average volume of 161,752. MDxHealth SA has a 1 year low of $1.35 and a 1 year high of $3.81. The company has a 50-day simple moving average of $2.71 and a 200 day simple moving average of $2.11. The company has a debt-to-equity ratio of 13.81, a current ratio of 1.31 and a quick ratio of 1.22. The stock has a market capitalization of $166.93 million, a P/E ratio of -4.01 and a beta of 1.49.

MDxHealth (NASDAQ:MDXH - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%.The company had revenue of $26.60 million during the quarter, compared to analysts' expectations of $26.60 million. MDxHealth has set its Q2 2025 guidance at -0.150--0.150 EPS. On average, equities research analysts expect that MDxHealth SA will post -1.15 earnings per share for the current year.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.